Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
OPK

OPK - OPKO Health Inc Stock Price, Fair Value and News

1.24USD-0.04 (-3.13%)Market Closed

Market Summary

OPK
USD1.24-0.04
Market Closed
-3.13%

OPK Alerts

  • 1 major insider buys recently.
  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

OPK Stock Price

View Fullscreen

OPK RSI Chart

OPK Valuation

Market Cap

864.3M

Price/Earnings (Trailing)

-3.42

Price/Sales (Trailing)

1.08

EV/EBITDA

-6.18

Price/Free Cashflow

-21.02

OPK Price/Sales (Trailing)

OPK Profitability

EBT Margin

-31.33%

Return on Equity

-20.15%

Return on Assets

-12.79%

Free Cashflow Yield

-4.76%

OPK Fundamentals

OPK Revenue

Revenue (TTM)

799.6M

Rev. Growth (Yr)

-26.89%

Rev. Growth (Qtr)

-4.52%

OPK Earnings

Earnings (TTM)

-252.4M

Earnings Growth (Yr)

-348%

Earnings Growth (Qtr)

-23.09%

Breaking Down OPK Revenue

Last 7 days

-3.9%

Last 30 days

-8.1%

Last 90 days

39.3%

Trailing 12 Months

-18.4%

How does OPK drawdown profile look like?

OPK Financial Health

Current Ratio

1.91

Debt/Equity

0

Debt/Cashflow

-10.19

OPK Investor Care

Buy Backs (1Y)

9.79%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024799.6M000
2023912.6M868.1M866.9M863.5M
20221.6B1.4B1.2B1.0B
20211.8B1.9B1.9B1.8B
2020891.0M965.8M1.2B1.4B
2019957.8M920.5M899.4M901.9M
2018954.5M925.6M929.4M990.3M
20171.1B1.1B1.1B966.0M
2016730.6M1.0B1.1B1.1B
201598.9M117.8M241.1M491.7M
201487.4M87.2M86.3M91.1M
201369.6M83.3M92.1M96.5M
201229.8M31.6M36.6M47.0M
201132.3M33.3M34.4M28.0M
2010012.4M20.5M28.5M
20090004.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of OPKO Health Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 23, 2024
frost phillip md et al
bought
126,937
1.26937
100,000
ceo & chairman
May 17, 2024
frost phillip md et al
bought
211,195
1.2878
163,997
ceo & chairman
Mar 18, 2024
frost phillip md et al
bought
437,100
0.8742
500,000
ceo & chairman
Mar 14, 2024
frost phillip md et al
bought
444,300
0.8886
500,000
ceo & chairman
Mar 13, 2024
frost phillip md et al
bought
463,750
0.9275
500,000
ceo & chairman
Mar 12, 2024
frost phillip md et al
bought
559,380
0.9323
600,000
ceo & chairman
Feb 28, 2024
frost phillip md et al
bought
496,150
0.9923
500,000
ceo & chairman
Feb 21, 2024
frost phillip md et al
bought
991,700
0.9917
1,000,000
ceo & chairman
Feb 07, 2024
frost phillip md et al
bought
1,462,800
0.9752
1,500,000
ceo & chairman

1–10 of 50

Which funds bought or sold OPK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
50.15
214
1,220
-%
May 24, 2024
Cetera Investment Advisers
added
447
60,714
78,834
-%
May 20, 2024
Virtu Financial LLC
new
-
26,000
26,000
-%
May 17, 2024
Kozak & Associates, Inc.
sold off
-
-
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.00
-164,620
507,212
-%
May 16, 2024
KLCM Advisors, Inc.
unchanged
-
-3,100
12,000
-%
May 16, 2024
JANE STREET GROUP, LLC
added
269
1,048,990
1,589,790
-%
May 16, 2024
FSA Wealth Management LLC
unchanged
-
-1,260
4,740
-%
May 16, 2024
COMERICA BANK
added
125
47,600
108,000
-%
May 16, 2024
AWM Investment Company, Inc.
added
18.18
-101,000
1,560,000
0.20%

1–10 of 42

Are Funds Buying or Selling OPK?

Are funds buying OPK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own OPK
No. of Funds

Unveiling OPKO Health Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.14%
39,751,293
SC 13G/A
Jan 24, 2024
frost phillip md et al
-
8
SC 13D/A
Jan 24, 2024
hsiao jane ph d
-
11
SC 13D/A
Jan 22, 2024
frost phillip md et al
-
8
SC 13D/A
Feb 21, 2023
frost phillip md et al
27.2%
213,891,935
SC 13D/A
Feb 09, 2023
vanguard group inc
5.32%
41,120,494
SC 13G/A
Aug 19, 2022
frost phillip md et al
26.0%
202,156,694
SC 13D/A
Aug 19, 2022
hsiao jane ph d
0.7%
5,127,404
SC 13D/A
Jun 29, 2022
zerhouni elias a.
2.9%
19,867,114
SC 13D
Jun 29, 2022
nabel gary j.
2.9%
20,012,985
SC 13D

Recent SEC filings of OPKO Health Inc

View All Filings
Date Filed Form Type Document
May 23, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 07, 2024
10-Q
Quarterly Report
May 07, 2024
8-K
Current Report
Mar 29, 2024
4
Insider Trading
Mar 29, 2024
4
Insider Trading
Mar 29, 2024
4
Insider Trading
Mar 29, 2024
4
Insider Trading
Mar 29, 2024
4
Insider Trading
Mar 29, 2024
4
Insider Trading

Peers (Alternatives to OPKO Health Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
188.8B
23.7B
-3.27% 4.65%
42.88
7.95
-8.94% -35.91%
41.6B
3.7B
-8.14% 4.67%
48.02
11.17
8.57% 23.94%
37.9B
6.6B
-15.71% 7.14%
30.51
5.75
-6.38% -8.07%
15.3B
9.3B
-2.09% 0.47%
18.1
1.65
-3.29% 6.68%
13.5B
1.2B
2.68% 117.25%
-37.03
11.2
39.26% 33.08%
12.2B
2.0B
-2.94% 78.57%
39.06
6.22
25.57% 21.62%
10.8B
4.1B
-9.94% 0.22%
24.27
2.62
0.49% -10.45%
MID-CAP
7.7B
2.5B
-21.45% -55.13%
-32.19
3.05
15.21% 53.51%
3.7B
603.7M
17.32% -20.21%
-8.02
6.12
25.21% 30.68%
3.7B
929.2M
27.97% -14.08%
2.4K
3.97
28.93% 111.61%
SMALL-CAP
739.1M
275.1M
-3.99% 71.79%
-4.03
2.69
-13.93% -126.97%
83.4M
31.1M
-0.85% -88.19%
-1.08
2.68
0.95% 19.75%
24.9M
9.0M
-28.06% -33.77%
-1.69
2.77
4.46% 45.80%
482.5K
5.5M
-83.45% -63.16%
-0.04
0.09
-68.52% -143.74%
183.8K
-
-50.00% -94.83%
-0.01
0.01
- -

OPKO Health Inc News

Latest updates
Simply Wall St09 Jun 202403:26 pm
Yahoo Finance06 Jun 202403:31 pm
Yahoo Finance08 May 202407:00 am
Zacks Investment Research2 months ago
Markets Insider5 months ago

OPKO Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-4.5%173,686,000181,905,000178,595,000265,418,000237,577,000185,340,000179,744,000309,893,000329,219,000401,332,000385,813,000442,408,000545,165,000494,676,000428,064,000301,207,000211,466,000224,344,000228,772,000226,368,000222,451,000
Operating Expenses-2.3%245,158,000250,949,000243,002,000258,393,000268,171,000240,610,000267,564,000320,632,000401,643,000464,416,000347,987,000436,837,000506,728,000445,318,000406,125,000274,028,000252,228,000336,807,000267,783,000273,628,000297,769,000
  S&GA Expenses-3.7%70,167,00072,883,00072,240,00079,794,00075,642,00073,997,00079,674,000101,464,000117,537,000138,214,500105,120,000113,236,000112,286,000101,823,50099,897,00077,721,00076,132,00079,130,00080,542,00088,475,00095,158,000
  R&D Expenses13.1%21,937,00019,394,00019,435,00018,159,00032,605,00019,528,50018,792,00017,254,00018,312,00021,007,00018,306,00018,222,00019,315,00017,454,50018,493,00017,608,00021,760,00023,038,00030,017,00028,286,00036,529,000
EBITDA Margin-110.8%-0.16-0.08-0.11-0.16-0.23-0.27-0.19-0.06-0.010.050.100.09---------
Interest Expenses122.6%7,686,0003,453,5003,384,0003,277,0003,391,0002,923,0003,017,0003,075,0003,420,00010,494,0003,503,000194,0004,689,000251,0005,079,000566,0005,012,000789,0005,673,0004,900,000511,000
Income Taxes77.6%-1,350,000-6,019,0006,075,0003,148,0001,233,000-16,975,500-40,327,00015,070,000-21,266,0007,495,5002,680,0004,754,000560,00013,596,000-3,178,0006,028,0001,171,0003,424,0001,769,0001,084,000783,000
Earnings Before Taxes-14.7%-83,183,000-72,494,000-78,378,000-16,450,000-16,997,000-102,183,000-126,375,000-86,312,000-76,650,000-65,812,50031,472,000-11,365,00031,681,00045,941,00020,649,00039,920,000-57,827,000-108,445,000-59,944,000-58,451,000-78,125,000
EBT Margin-46.8%-0.31-0.21-0.25-0.30-0.36-0.39-0.29-0.14-0.08-0.010.050.05---------
Net Income-23.1%-81,836,000-66,483,000-84,473,000-19,640,000-18,267,000-85,231,000-86,091,000-101,650,000-55,433,000-73,775,00028,739,000-16,186,00031,078,00032,298,00023,717,00033,703,000-59,132,000-112,350,000-62,007,000-59,806,000-80,762,000
Net Income Margin-44.3%-0.32-0.22-0.24-0.24-0.32-0.33-0.26-0.14-0.07-0.020.040.04---------
Free Cashflow7.1%-35,566,000-38,294,00033,109,000-365,000-22,647,000-31,620,000-32,236,000-11,477,000-19,856,000-5,643,00033,395,000-15,452,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.9%1,9742,0122,0572,1592,1702,1672,2252,3702,3072,4002,4182,4222,5202,4732,3712,3242,2332,3092,3702,4562,575
  Current Assets26.4%391309357434406395414495754823558547599523428360274324293344435
    Cash Equivalents-21.1%76.0096.0013910811115318121010213514966.0090.0072.0036.0022.0035.0085.0065.00111207
  Inventory-9.6%59.0066.0069.0074.0075.0074.0071.0083.0099.0087.0011313515913211273.0059.0053.0050.0048.0045.00
  Net PPE-14.9%64.0075.0078.0079.00-83.00------139141134131127127129137140
  Goodwill-11.3%531598594597597596573579519710675677676719676672670710696700699
Liabilities15.9%721622612624618606596651692715652679823802748735684695728747813
  Current Liabilities2.1%204200201226222213267215309330283304404375336280245249270283396
  Long Term Debt-47.8%4.008.00--------2.004.003.004.004.004.004.004.004.005.004.00
    LT Debt, Current-8.5%2.002.00-------------------
    LT Debt, Non Current-----------2.004.003.004.004.004.004.004.004.005.004.00
Shareholder's Equity-9.8%1,2531,3891,4451,5351,5521,5621,6291,7191,6151,6851,7661,7431,6971,6721,6241,5881,5491,6151,6421,7091,763
  Retained Earnings-4.1%-2,093-2,011-1,945-1,860-1,841-1,822-1,737-1,651-1,549-1,511-1,438-1,466-1,450-1,481-1,514-1,537-1,571-1,511-1,398-1,336-1,276
  Additional Paid-In Capital-1.4%3,3863,4333,4303,4273,4253,4223,4193,4143,1913,2223,2193,2143,1563,1533,1503,1473,1453,1433,0653,0623,059
Accumulated Depreciation-100.0%-157---142---------------
Shares Outstanding-6.0%707752752752752719708713660648647647---------
Float----904---1,061---1,607---1,362---867-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations7.1%-35,566-38,29433,109-365-22,647-31,620-32,236-11,477-19,856-5,64333,395-15,45226,03734,25863,011-14,423-43,370-46,037-23,866-53,631-48,988
  Share Based Compensation-2.9%2,6002,6773,2002,8002,7003,2093,4004,3007,6003,6713,8223,4602,6472,1232,7401,5862,4512,4143,4283,1224,457
Cashflow From Investing-209.9%-4,395-1,418-3,572-5,491-7,717-7,872-4,682108,495-4,903-8,67954,576-8,842-1,106-6,7445,501-11,465-5,619-3,756-2,191-3,191-4,132
Cashflow From Financing649.5%20,613-3,7512,1053,462-13,11910,1448,44412,274-7,891833-4,255264-7,1928,108-54,46112,888-1,61170,644-19,995-39,276163,875
  Buy Backs-50,000--------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

OPK Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Revenues$ 173,686$ 237,577
Costs and expenses:  
Selling, general and administrative70,16775,642
Research and development21,93732,605
Contingent consideration0136
Amortization of intangible assets21,43721,474
Total costs and expenses245,158268,171
Operating loss(71,472)(30,594)
Other income and (expense), net:  
Interest income8131,030
Interest expense(7,686)(3,391)
Fair value changes of derivative instruments, net(26,161)(1,059)
Other income, net21,32317,017
Other income (expense), net(11,711)13,597
Loss before income taxes and investment losses(83,183)(16,997)
Income tax benefit (provision)1,350(1,233)
Net loss before investment losses(81,833)(18,230)
Loss from investments in investees(3)(37)
Net loss$ (81,836)$ (18,267)
Loss per share, basic and diluted:  
Loss per share (in dollars per share)$ (0.12)$ (0.02)
Weighted average common shares outstanding, basic and diluted (in shares)706,882,189751,506,257
Service [Member]  
Revenues:  
Revenues$ 126,890$ 132,368
Costs and expenses:  
Cost of Goods and Services Sold109,873114,059
Product [Member]  
Revenues:  
Revenues38,04740,383
Costs and expenses:  
Cost of Goods and Services Sold21,74424,255
Transfer of Intellectual Property and Other [Member]  
Revenues:  
Revenues$ 8,749$ 64,826

OPK Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 75,639$ 95,881
Accounts receivable, net111,367123,379
Inventory, net59,36665,697
Other current assets and prepaid expenses24,65224,519
Assets held for sale120,2790
Total current assets391,303309,476
Property, plant and equipment, net64,16575,429
Intangible assets, net680,034740,283
In-process research and development195,000195,000
Goodwill530,615598,260
Investments40,99016,082
Operating lease right-of-use assets63,33168,088
Other assets8,5789,080
Total assets1,974,0162,011,698
Current liabilities:  
Accounts payable71,15769,677
Accrued expenses88,77290,086
Current maturities of operating leases11,74212,996
Current portion of convertible notes1700
Current portion of lines of credit and notes payable22,82027,293
Liabilities associated with assets held for sale9,6770
Total current liabilities204,338200,052
Operating lease liabilities50,93154,140
Long term portion of convertible notes323,108214,325
Deferred tax liabilities121,635126,773
Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit21,19627,189
Total long-term liabilities516,870422,427
Total liabilities721,208622,479
Equity:  
Common Stock - $0.01 par value, 1,000,000,000 shares authorized; 726,791,854 and 781,936,885 shares issued at March 31, 2024 and December 31, 2023, respectively7,2697,820
Treasury Stock - 29,772,753, and 8,655,082 shares at March 31, 2024 and December 31, 2023, respectively(1,791)(1,791)
Additional paid-in capital3,386,1473,433,006
Accumulated other comprehensive loss(45,195)(38,030)
Accumulated deficit(2,093,622)(2,011,786)
Total shareholders’ equity1,252,8081,389,219
Total liabilities and equity$ 1,974,016$ 2,011,698
OPK
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
 CEO
 WEBSITEopko.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES4196

OPKO Health Inc Frequently Asked Questions


What is the ticker symbol for OPKO Health Inc? What does OPK stand for in stocks?

OPK is the stock ticker symbol of OPKO Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of OPKO Health Inc (OPK)?

As of Fri Jun 14 2024, market cap of OPKO Health Inc is 864.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OPK stock?

You can check OPK's fair value in chart for subscribers.

What is the fair value of OPK stock?

You can check OPK's fair value in chart for subscribers. The fair value of OPKO Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of OPKO Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OPK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is OPKO Health Inc a good stock to buy?

The fair value guage provides a quick view whether OPK is over valued or under valued. Whether OPKO Health Inc is cheap or expensive depends on the assumptions which impact OPKO Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OPK.

What is OPKO Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, OPK's PE ratio (Price to Earnings) is -3.42 and Price to Sales (PS) ratio is 1.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on OPKO Health Inc's stock?

In the past 10 years, OPKO Health Inc has provided -0.184 (multiply by 100 for percentage) rate of return.